HIIFS
TCRT icon

Harel Insurance Investments & Financial Services’s Alaunos Therapeutics TCRT Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-60
Closed -$35K – 523
2019
Q1 		$35K Buy
+60
New +$25.1K ﹤0.01% 302

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Harel Insurance Investments & Financial Services's TCRT Position: Q2 2019 in Review

Harel Insurance Investments & Financial Services sold out of Alaunos Therapeutics (TCRT) in Q2 2019, closing a stake of 60 shares — an estimated $35K sold.

Harel Insurance Investments & Financial Services first reported a position in TCRT in Q1 2019 and held it in 1 quarter. The position peaked at $35K in Q1 2019. 140 funds tracked by Wall St. Rank hold TCRT as of Q2 2019.

  • Harel Insurance Investments & Financial Services reported no remaining Alaunos Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 60 Alaunos Therapeutics shares in Q2 2019, an estimated $35K.
  • Harel Insurance Investments & Financial Services first reported a position in Alaunos Therapeutics in Q1 2019 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Alaunos Therapeutics position peaked at $35K in Q1 2019.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2019.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2019, filed 22 Jul 2019.